RT @Trankill34@twitter.com

Peptide-based PROTACs: Current Challenges and Future Perspectives https://www.eurekaselect.com/article/129156

🐦🔗: https://twitter.com/Trankill34/status/1620409844279963648

RT @Trankill34@twitter.com

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development https://www.sciencedirect.com/science/article/pii/S2666246922000118

🐦🔗: https://twitter.com/Trankill34/status/1620326531666153472

RT @Trankill34@twitter.com

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC https://onlinelibrary.wiley.com/doi/10.1002/ctm2.1191#.Y9jGeHWIZwg.twitter

🐦🔗: https://twitter.com/Trankill34/status/1620326732342640643

RT @Trankill34@twitter.com

Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01712#.Y9jGIuWsEKY.twitter

🐦🔗: https://twitter.com/Trankill34/status/1620326372261629954

An affinity-directed phosphatase (AdPhosphatase) system for targeted dephosphorylation of specific phospho-substrates - a useful tool as we start to build PHORC/PHIC induced proximity modulators #inducedproximity #PFEColleague https://bit.ly/3Hl9Kj5

RT @AlbertBourla@twitter.com

Today on #WorldNTDDay, we recognize the need to address neglected tropical diseases such as #trachoma. So I am incredibly proud to celebrate the donation of the one billionth dose of our antibiotic as part global efforts to eliminate this disease. https://bit.ly/3kPHe1s

🐦🔗: https://twitter.com/AlbertBourla/status/1620093566944157702

RT @HartungIngo@twitter.com

One of my must-read papers in J. Med. Chem. @ACSBioMed@twitter.com is the annual compilation of fragment-to-lead cases. The 2021 edition comprises 28 entries, several for difficult-to-drug targets. For kinases fragments can provide an entry into structure-based design https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01827

🐦🔗: https://twitter.com/HartungIngo/status/1619997596784955392

RT @HartungIngo@twitter.com

Progress in targeted protein degradation (#TPD) is limited by a scarcity of know-how about human E3s. High quality chemical probes can help to bridge that gap as now exemplified for #GID4 by scientists @pfizer@twitter.com & @thesgconline@twitter.com #OpenScience https://www.biorxiv.org/content/10.1101/2023.01.17.524225v1 @biorxivpreprint@twitter.com

🐦🔗: https://twitter.com/HartungIngo/status/1619664917963104257

RT @Trankill34@twitter.com

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence https://pubs.acs.org/doi/10.1021/jacs.2c11098#.Y9bFLNXu3hQ.twitter

🐦🔗: https://twitter.com/Trankill34/status/1619775665225732097

https://www.linkedin.com/posts/activity-7024793444447350784-UU2i?utm_source=post_nba&utm_medium=member_ios&utm_campaign=share_via

Know Plan Go if You're at High Risk for Severe COVID-19 #PFEColleague https://bit.ly/3wwSqTc

RT @AlbertBourla@twitter.com

Thank you @US_FDA@twitter.com for a robust discussion on how we can continue helping to protect people from #COVID19. We look forward to working together on a streamlined plan for future vaccine updates.

🐦🔗: https://twitter.com/AlbertBourla/status/1618954594721345537

RT @Trankill34@twitter.com

Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives - now published in RSC Medicinal Chemistry https://pubs.rsc.org/en/content/articlelanding/2023/md/d2md00347c

🐦🔗: https://twitter.com/Trankill34/status/1618512296065773571

RT @endpts@twitter.com

Grey Wolf Therapeutics brings in $49 million in a Series B round led by Pfizer Ventures and Earlybird Venture Capital.

https://endpts.com/grey-wolf-reels-in-49m-to-enter-the-clinic-for-new-immunotherapy-target/

🐦🔗: https://twitter.com/endpts/status/1618597120549818371

RT @statnews@twitter.com

Updated Covid-19 booster still providing strong protection against newer variants, CDC study finds https://trib.al/2gjnHvW

🐦🔗: https://twitter.com/statnews/status/1618308583388504081

RT @MonteRosaTx@twitter.com

Stop by the Molecular Glue Degrader Summit today to hear Sharon Townson discuss the advanced capabilities of Monte Rosa's QuEEN platform.

🐦🔗: https://twitter.com/MonteRosaTx/status/1618224310992408579

RT @MykhailiukChem@twitter.com

Is it BCP? Cubane?
Oh no, it is O-[2.2.2] - ideal Ph-bioisoster!
@ChemRxiv@twitter.com: http://bit.ly/3XAJKY1

🐦🔗: https://twitter.com/MykhailiukChem/status/1618127144756088833

RT @GunningLabUofT@twitter.com

The mystery of @genentech@twitter.com's monovalent BRD degraders equipped with a propargyl "degradation tail" has been solved by researchers @abbvie@twitter.com: a #CRISPR screen reveals molecular glue-like recruitment of #DCAF16.
#TargetedProteinDegradation #MonovalentDegraders https://pubs.acs.org/doi/full/10.1021/acschembio.2c00747

🐦🔗: https://twitter.com/GunningLabUofT/status/1618244850817564675

Local Cysteine Capture (Cys-LoC), and Local Cysteine Oxidation (Cys-LOx) methods can define the subcellular cysteinome and inflammation-responsive mitochondrial redoxome #inducedproximity #PFEColleague https://bit.ly/3WAjyew

Providing mentors for American Corporate Partners' program is one of the many ways Pfizer is helping veterans successfully transition to meaningful civilian careers. Learn more about our partnership! #nationalmentoringmonth #PFEColleague https://bit.ly/3H4j6Q3